Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
This study has been completed.
Study NCT00078845 Information provided by National Cancer Institute (NCI)
First Received: March 8, 2004 Last Updated: May 9, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Lung Cancer
Neurotoxicity
Ovarian Cancer
Prostate Cancer
Additional conditions recognized in this trial
Breast Neoplasms
Lung Neoplasms
Neurotoxicity Syndromes
Ovarian Neoplasms
Peripheral Nervous System Diseases
Prostatic Neoplasms
More general conditions related to this trial
Adnexal Diseases
Breast Diseases
Disorders of Environmental Origin
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Diseases, Male
Genital Neoplasms, Female
Genital Neoplasms, Male
Gonadal Disorders
Lung Diseases
Neoplasms
Neoplasms by Site
Nervous System Diseases
Neuromuscular Diseases
Ovarian Diseases
Poisoning
Prostatic Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Skin Diseases
Thoracic Neoplasms
Urogenital Neoplasms
Interventions listed in this trial
amifostine trihydrate
Additional drug interventions recognized in this trial
Amifostine
Paclitaxel
More general drug interventions related to this trial
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Radiation-Protective Agents
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Back to top of Main Content